此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

血管内血栓切除术后动脉内注射替奈普酶治疗大血管闭塞中风 (TNK-FLOW)

2026年9月24日 更新者:Wake Forest University Health Sciences

The purpose of this study is to determine the safety and feasibility of using intra-arterial Tenecteplase in patients undergoing blood clot extraction for treatment of acute ischemic (non-bleeding) stroke. Intravenous Tenecteplase is FDA-approved to treat patients with an ischemic stroke presenting within the 0-3-hour time window.

研究概览

详细说明

The primary objective of this study is to determine the safety and feasibility of intra-arterial Tenecteplase in selected patients with persistent post-thrombectomy hypoperfusion on computed tomography perfusion based on symptomatic intracranial hemorrhage (parenchymal hematoma type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage producing decline from the initial NIHSS of ≥ 4 points) at 24-36 hours.

研究类型

介入性

注册 (估计的)

40

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • North Carolina
      • Charlotte、North Carolina、美国、28207
        • Atrium Health Neurosciences Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patient/legally authorized representative has signed the Informed Consent Form
  • Ability to comply with the study protocol, in the investigator's judgment
  • Functionally independent (modified Rankin scale 0-2) prior to presentation
  • Baseline National Institutes of Health Stroke Scale (NIHSS) ≥ 6
  • Clinical syndrome consistent with occlusion of the internal carotid artery (ICA) or proximal middle cerebral artery (MCA), presenting within 4.5- to 24-hours of TLKW
  • Evidence of ICA, MCA-M1, or MCA-M2 occlusion on baseline computed tomography angiogram (CTA) or magnetic resonance angiogram (MRA). ICA/MCA tandem occlusions may be enrolled
  • Alberta Stroke Program Early Computed Tomography Score ≥ 6 on pre-thrombectomy unenhanced CT as determined by treating neurologist or reading radiologist
  • Pre-thrombectomy CTP or MRP with core infarction (cerebral blood flow < 30%) < 70 ml, mismatch ratio ≥ 1.8, mismatch volume ≥ 15 ml (completed within 120 minutes of skin puncture for thrombectomy). If skin puncture occurs more than 120 minutes after the pre-thrombectomy CTP, enrollment may proceed at the PI's discretion.
  • Endovascular thrombectomy of ICA, MCA-M1 or MCA-M2 occlusion performed according to local standard of care, defined as at least completing the initial diagnostic angiogram
  • CTP performed with RAPID AI AngioFlowTM within 30 minutes of thrombectomy completion
  • Modified thrombolysis in cerebral infarction (mTICI) 2b-3 revascularization following endovascular thrombectomy (EVT) (or after initial diagnostic angiogram)
  • Presence of Tm > 6 lesion on post-EVT CTP of adequate quality for interpretation in the distribution of the symptomatic occlusion

Exclusion Criteria:

  • Current participation in another investigational drug or device study
  • Known hypersensitivity or allergy to any ingredients of tenecteplase
  • Active internal bleeding
  • Known bleeding diathesis (e.g., Alzheimer's patients taking lecanemab)
  • Systolic blood pressure > 185 mm Hg or diastolic blood pressure > 110 mm Hg after EVT, refractory to medical therapy
  • Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR > 1.7
  • Use of one of the new oral anticoagulants within the last 48 hours (dabigatran, rivaroxaban, apixaban, edoxaban)
  • Treatment with a thrombolytic within the last 3 months prior to randomization
  • Baseline platelet count < 100,000/mcL (results must be available prior to treatment)
  • Baseline blood glucose > 400 mg/dL (22.20 mmol/L)
  • Baseline blood glucose < 50 mg/dL; needs to be normalized prior to randomization
  • Intracranial or intraspinal surgery or trauma within 2 months
  • Intracranial malignant neoplasm, arteriovenous malformation, or unsecured aneurysm > 1 cm
  • Other serious, advanced, or terminal illness (investigator's judgment) or life expectancy is less than 6 months
  • History of acute ischemic stroke in the last 90 days
  • History of hemorrhagic stroke
  • Presumed septic embolus; suspicion of bacterial endocarditis
  • Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was to be performed
  • Pregnant
  • Acute intracranial hemorrhage on pre-thrombectomy imaging or suspected acute intracranial hemorrhage after EVT
  • Acute bilateral strokes on initial imaging
  • Multiple acute intracranial occlusions (except ICA/MCA) on initial CTA or MRA
  • Significant hemispheric mass effect or any amount of midline shift due to acute stroke
  • Placement of cervical carotid or intracranial stent during thrombectomy procedure requiring dual antiplatelet therapy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Intra-arterial Tenecteplase

Following endovascular thrombectomy for large vessel occlusion stroke one-time dose of intra-arterial Tenecteplase (0.125 mg/kg, maximum dose 12.5 mg) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist.

One-time dose of intra-arterial tenecteplase post-thrombectomy

安慰剂比较:Intra-arterial Saline

Following endovascular thrombectomy for large vessel occlusion stroke one-time dose of saline (0.9% NaCl solution) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist.

One-time dose of intra-arterial saline post-thrombectomy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Participants with Change in Symptomatic Intracranial Hemorrhage
大体时间:Hour 36

Number of participants with symptomatic intracranial hemorrhage (parenchymal hematoma type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage) producing decline from the initial National Institutes of Health Stroke Scale (NIHSS) of ≥ 4 points.

Hour 36
Participants with Parenchymal Hematoma Type 1
大体时间:24 Hours

Number of participants with parenchymal hematoma type 1

24 Hours
Participants with Parenchymal Hematoma Type 2
大体时间:24 Hours

Number of participants with parenchymal hematoma type 2

24 Hours
30-Day Mortality Count
大体时间:Day 30

Number of patients expired

Day 30
90-Day Mortality Count
大体时间:Day 90

Number of patients expired

Day 90
Number of Grade 3 Adverse Events
大体时间:Hour 24

Total number of grade 3 adverse events

Hour 24
Number of Grade 3 Adverse Events
大体时间:Day 5

Total number of grade 3 adverse events

Day 5
Number of Grade 3 Adverse Events
大体时间:Day 30

Total number of grade 3 adverse events

Day 30
Number of Grade 3 Adverse Events
大体时间:Day 90

Total number of grade 3 adverse events

Day 90

其他结果措施

结果测量
措施说明
大体时间
Proportion of subjects achieving early neurological improvement
大体时间:Hour 24

Proportion of subjects achieving early neurological improvement, defined as National Institutes of Health Stroke Scale (NIHSS) reduction by ≥ 4 points or total NIHSS 0-2

Hour 24
Proportion of subjects achieving delayed neurological improvement
大体时间:Day 30, Day 90

Proportion of subjects achieving delayed neurological improvement, defined as National Institutes of Health Stroke Scale (NIHSS) reduction by ≥ 4 points or total NIHSS 0-2

Day 30, Day 90
Ordinal Modified Rankin Scale score
大体时间:Day 90

Modified Rankin scale scores range from 0-6. Higher score indicates greater disability.

Day 90
Participants with Change in Modified Rankin Scale Score 0-2 Points
大体时间:Day 90

Number of participants with change in Modified Rankin Scale score of 0-2 points or return to baseline modified Rankin scale score.

Day 90
Participants with Change in Modified Rankin Scale Score 0-1 Points
大体时间:Day 90

Number of participants with change in Modified Rankin Scale score of 0-1 points or return to baseline modified Rankin scale score.

Day 90
Participants with Change in Modified Rankin Scale Score 0-3 Points
大体时间:Day 90

Number of participants with change in Modified Rankin Scale score of 0-3 points or return to baseline modified Rankin scale score.

Day 90
Change in Infarct Volume
大体时间:Hour 24

Change in infarct volume on follow up CT or MRI

Hour 24
Barthel Index Score
大体时间:Day 90

Number of participants with Barthel Index score ≥ 95.

Day 90
Median EuroQol-5-Dimension (EQ-5D) Index
大体时间:Day 90

Median EuroQol-5-Dimension (EQ-5D) index has a score range of -0.573 to 1. Higher score indicates better quality score.

Day 90

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Rahul Karamchandani, MD、Atrium Health Neurosciences Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月22日

初级完成 (估计的)

2028年6月1日

研究完成 (估计的)

2028年6月1日

研究注册日期

首次提交

2025年1月13日

首先提交符合 QC 标准的

2025年1月13日

首次发布 (实际的)

2025年1月17日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅